ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 604

Do Illness Perceptions and Coping Change over Time in Patients Recently Diagnosed with Axial Spondyloarthritis? A 2-Year Follow-Up Study in the SPACE Cohort

Miranda van Lunteren1, Robert B.M. Landewé 2, Camilla Fongen 3, Roberta Ramonda 4, Désirée van der Heijde 1 and Floris van Gaalen 1, 1Leiden University Medical Center, Leiden, Netherlands, 2Amsterdam University Medical Center, Amsterdam, Netherlands, 3Diakonhjemmet Hospital, Oslo, Norway, 4University of Padova, Padova, Italy

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: axial spondyloarthritis, coping, health outcome and clinical research, longitudinal studies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: We have previously shown that in patients with recently diagnosed axial SpA (axSpA), illness perceptions had a negative impact on the relationship between back pain and Health-Related Quality of Life (HRQoL) and work productivity loss (WPL). We investigated if illness perceptions and coping strategies change after axSpA diagnosis.

Methods: Patients recently diagnosed with axSpA and ≥1 follow-up visit (1 year and/or 2 years) in the SPACE-cohort were included in the analysis. Mixed linear models were used to test if illness perceptions (measured by the Revised Illness Perception Questionnaire (IPQ-R), Table 1) and coping (Coping with Rheumatic Stressors (CORS), Table 1) as well as back pain (scale 0-10), HRQoL (physical (PCS) and mental component summary (MCS), scale 0-100, 36-item Short-Form Health Survey (SF-36)), WPL and activity impairment (Work Productivity and Activity Impairment (WPAI, range 0-100%)), changed over time. Results were stratified for gender and age when the interaction term was statistically significant (p< 0.10).

Results: In total, 150 axSpA patients (mean age 30.4 years, 51% female, 65% HLA-B27+) were analysed. At baseline mean back pain (SD) was 4.0 (2.5), PCS was 28.8 (14.0), MCS was 46.6 (13.6), WPL was 34.1% (29.8) and activity impairment was 38.7% (27.9). Over two years, the percentage patients with ASDAS inactive or low disease activity increased from 39% to 68%, back pain (mean change ± SD is -1.5 ± 2.2) and activity impairment (-14.4% ± 27.2) decreased, PCS (11.1 ± 13.3) and WPL (-15.3% ± 28.7) improved statistically significantly (all p< 0.05), but MCS did not change (0.7 ± 13.9, p=0.201).

Illness perceptions and coping strategies showed little and no clinically meaningful change over time (Table 2, 3). Over two years patients remained having negative illness perceptions (which were important in the association between back pain and health outcomes in the previous study). For example, at two years patients strongly believed that their illness had severe consequences (‘consequences’), they had negative emotions such as feeling upset or having fear towards their illness (‘emotional representation’), and had strong beliefs in chance or bad luck (‘chance’) being the cause for axSpA.

Patients most often coped with pain by putting pain in perspective (‘comforting cognitions’), most often coped with limitations by trying to be optimistic (‘optimism’), and most often coped with dependence of other people by considering feelings of these people (‘consideration’).

Conclusion: Whilst back pain, disease activity, and health outcomes clearly improved over 2 years, illness perceptions about their illness and coping strategies to live with their illness remained remarkably stable in patients recently diagnosed with axSpA.


Table 1 Overview of illness perceptions and coping strategies measured by the IPQ-R and CORS questionnaires

Table 1 Overview of illness perceptions and coping strategies measured by the IPQ-R and CORS questionnaires


Table 2 Illness perceptions over time in axSpA patients with baseline and or 1- or 2-years data in the SPACE cohort

Table 2 Illness perceptions over time in axSpA patients with baseline and/or 1- or 2-years data in the SPACE cohort -n=150-


Table 3 Coping over time in axSpA patients with baseline and or 1- or 2-years data in the SPACE cohort

Table 3 Coping strategies over time in axSpA patients with baseline and/or 1- or 2-years data in the SPACE cohort -n=150-


Disclosure: M. van Lunteren, None; R. Landewé, Abbott, 2, 5, 8, Abbott, Amgen, Bristol-Myers Squibb, Centocor, Merck, Pfizer, Roche, Schering-Plough, UCB, Wyeth, 8, Abbott, Amgen, Centocor, Novartis, Pfizer, Roche, Schering-Plough, UCB, Wyeth, 2, AbbVie, 5, Abbvie, 5, 8, AbbVie, Ablynx, Amgen, Astra-Zeneca, Bristol-Myers Squibb, Centocor, GSK, Novartis, Merck, Pfizer, Roche, Schering- Plough, UCB, Wyeth, 5, Ablynx, 5, Amgen, 2, 5, 8, AstraZeneca, 5, BMS, 5, 8, Bristol Myers Squibb, 5, 8, Bristol-Myers Squibb, 5, Celgene, 5, 8, Centocor, 2, 5, 8, Director of Rheumatology Consultancy BV, which is a registered company under Dutch law, 6, Eli Lilly, 5, 8, Eli Lilly and Company, 5, Eli-Lilly, 5, 8, Galapagos, 5, 8, Gilead, 5, 8, GlaxoSmithKline, 5, Glaxo-Smith-Kline, 5, 8, Janssen, 5, 8, Merck, 5, 8, MSD, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Rheumatology bv, 4, Rheumatology Consultancy BV, 9, Roche, 2, 5, 8, Schering-Plough, 2, 5, 8, UCB, 5, 8, UCB Pharma, 2, 5, 8, Wyeth, 2, 5, 8; C. Fongen, None; R. Ramonda, None; D. van der Heijde, AbbVie, 5, AbbVie, Amgen, Astellas, AstraZeneca, BMS, 5, Amgen, 5, Astellas, 5, 9, Astellas Pharma, 5, AstraZeneca, 5, BMS, 5, Boehringer Ingelheim, 5, Boehringer Ingelheim, Celgene, Daiichi, Eli-Lilly, Galapagos, Gilead, GSK, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB, 5, Boehringer-Ingelheim, 5, Bristol-Myers Squibb, 5, Celgene, 5, Daiichi, 5, 9, Daiichi Sankyo, 5, Director of Imaging Rheumatology, 6, Director of Imaging Rheumatology bv, 9, Eli Lilly, 5, Eli Lilly and Company, 5, Eli-Lilly, 5, Galapagos, 5, Gilead, 5, Gilead Sciences, Inc., 5, GlaxoSmithKline, 5, Glaxo-Smith-Kline, 5, GSK, 5, 8, Imaging Rheumatology bv, 9, Imaging Rheumatology BV, 9, Imaging Rheumatology bv., 9, Janssen, 5, 8, Janssen Pharmaceutica, 5, Merck, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Pfizer Inc, 5, Regeneron, 5, 8, Rheumatology bv, 4, 9, Roche, 5, 8, Sanofi, 5, 8, Takeda, 5, 8, Takeda Pharmaceutical Company, 5, UCB, 5, 8, UCB Pharma, 5; F. van Gaalen, None.

To cite this abstract in AMA style:

van Lunteren M, Landewé R, Fongen C, Ramonda R, van der Heijde D, van Gaalen F. Do Illness Perceptions and Coping Change over Time in Patients Recently Diagnosed with Axial Spondyloarthritis? A 2-Year Follow-Up Study in the SPACE Cohort [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/do-illness-perceptions-and-coping-change-over-time-in-patients-recently-diagnosed-with-axial-spondyloarthritis-a-2-year-follow-up-study-in-the-space-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/do-illness-perceptions-and-coping-change-over-time-in-patients-recently-diagnosed-with-axial-spondyloarthritis-a-2-year-follow-up-study-in-the-space-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology